Literature DB >> 21512863

Summary of prognostic factors and patient selection for extrapleural pneumonectomy in the treatment of malignant pleural mesothelioma.

Christopher Cao1, Tristan D Yan, Paul G Bannon, Brian C McCaughan.   

Abstract

BACKGROUND: Extrapleural pneumonectomy (EPP) has been shown to improve long-term survival outcomes in selected patients with malignant pleural mesothelioma (MPM). The present study aimed to evaluate potential prognostic factors on overall survival for patients who underwent EPP for MPM and to examine the patient selection process in major referral centers that perform EPP.
METHODS: A systematic review of the current literature was performed using 5 electronic databases. Relevant studies with prognostic data on overall survival for patients with MPM treated by EPP were included for review. Two reviewers independently assessed each included study.
RESULTS: A total of 17 studies from 13 institutions containing the most updated and complete data on prognostic factors for patients with MPM who underwent EPP were included for review. A number of quantitative, clinical, and treatment-related factors were identified to have significant impact on overall survival.
CONCLUSIONS: Patients with nonepithelial MPM and nodal involvement have consistently demonstrated to have a worse prognosis after EPP. Their eligibility as candidates for EPP should be questioned. The preoperative patient selection process currently differs greatly between institutions and should focus on identifying patients with nonepithelial histologic subtypes and nodal involvement to exclude them as EPP surgical candidates in the future.

Entities:  

Mesh:

Year:  2011        PMID: 21512863     DOI: 10.1245/s10434-011-1728-x

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  10 in total

1.  "Lower door open thoracotomy": a feasible approach for extra-pleural pneumonectomy.

Authors:  Giovanni Leuzzi; Kenji Kawamukai; Calogero Porrello; Sergio Forti Parri; Gian Marco Guiducci; Nicola Lacava
Journal:  J Thorac Dis       Date:  2013-12       Impact factor: 2.895

Review 2.  Landmark Trials in the Surgical Management of Mesothelioma.

Authors:  Taylor Kantor; Elliot Wakeam
Journal:  Ann Surg Oncol       Date:  2021-01-31       Impact factor: 5.344

3.  The application of cold-plasma coagulation on the visceral pleura results in a predictable depth of necrosis without fistula generation.

Authors:  Martin Hoffmann; Anita Ulrich; Erik Schloericke; Stefan Limmer; Jens Karsten Habermann; Heike Wolken; Hans-Peter Bruch; Peter Kujath
Journal:  Interact Cardiovasc Thorac Surg       Date:  2011-12-22

4.  Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Hedy L Kindler; Nofisat Ismaila; Samuel G Armato; Raphael Bueno; Mary Hesdorffer; Thierry Jahan; Clyde Michael Jones; Markku Miettinen; Harvey Pass; Andreas Rimner; Valerie Rusch; Daniel Sterman; Anish Thomas; Raffit Hassan
Journal:  J Clin Oncol       Date:  2018-01-18       Impact factor: 44.544

5.  Systematic review of trimodality therapy for patients with malignant pleural mesothelioma.

Authors:  Christopher Cao; David Tian; Con Manganas; Phoebe Matthews; Tristan D Yan
Journal:  Ann Cardiothorac Surg       Date:  2012-11

Review 6.  Modern management of malignant pleural mesothelioma.

Authors:  Shivani C Patel; Jonathan E Dowell
Journal:  Lung Cancer (Auckl)       Date:  2016-05-03

7.  EphB4 as a therapeutic target in mesothelioma.

Authors:  Ren Liu; Benjamin D Ferguson; Yue Zhou; Kranthi Naga; Ravi Salgia; Parkash S Gill; Valery Krasnoperov
Journal:  BMC Cancer       Date:  2013-05-30       Impact factor: 4.430

8.  Circulating fibrinogen is a prognostic and predictive biomarker in malignant pleural mesothelioma.

Authors:  B Ghanim; M A Hoda; T Klikovits; M-P Winter; A Alimohammadi; M Grusch; B Dome; M Arns; P Schenk; M Jakopovic; M Samarzija; L Brcic; M Filipits; V Laszlo; W Klepetko; W Berger; B Hegedus
Journal:  Br J Cancer       Date:  2014-01-16       Impact factor: 7.640

9.  Management of malignant pleural mesothelioma-part 2: therapeutic approaches : Consensus of the Austrian Mesothelioma Interest Group (AMIG).

Authors:  Mir Alireza Hoda; Thomas Klikovits; Madeleine Arns; Karin Dieckmann; Sabine Zöchbauer-Müller; Christian Geltner; Bernhard Baumgartner; Peter Errhalt; Barbara Machan; Wolfgang Pohl; Jörg Hutter; Josef Eckmayr; Michael Studnicka; Martin Flicker; Peter Cerkl; Walter Klepetko
Journal:  Wien Klin Wochenschr       Date:  2016-07-25       Impact factor: 1.704

10.  Management of malignant pleural mesothelioma - part 3 : Data from the Austrian Mesothelioma Interest Group (AMIG) database.

Authors:  Thomas Klikovits; Mir Alireza Hoda; Yawen Dong; Madeleine Arns; Bernhard Baumgartner; Peter Errhalt; Christian Geltner; Barbara Machan; Wolfgang Pohl; Jörg Hutter; Josef Eckmayr; Michael Studnicka; Martin Flicker; Peter Cerkl; Klaus Kirchbacher; Walter Klepetko
Journal:  Wien Klin Wochenschr       Date:  2016-07-25       Impact factor: 1.704

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.